143 58

Full metadata record

DC FieldValueLanguage
dc.contributor.author์œค์ฑ„์˜ฅ-
dc.date.accessioned2022-11-04T01:01:30Z-
dc.date.available2022-11-04T01:01:30Z-
dc.date.issued2021-02-
dc.identifier.citationADVANCED SCIENCE, v. 8, no. 7, article no. 2001308en_US
dc.identifier.issn2198-3844en_US
dc.identifier.urihttps://onlinelibrary.wiley.com/doi/10.1002/advs.202001308en_US
dc.identifier.urihttps://repository.hanyang.ac.kr/handle/20.500.11754/176274-
dc.description.abstractImmunogenic cell death (ICD) is distinguished by the release of tumor-associated antigens (TAAs) and danger-associated molecular patterns (DAMPs). This cell death has been studied in the field of cancer immunotherapy due to the ability of ICD to induce antitumor immunity. Herein, endoplasmic reticulum (ER) stress-mediated ICD inducing fluorinated mitochondria-disrupting helical polypeptides (MDHPs) are reported. The fluorination of the polypeptide provides a high helical structure and potent anticancer ability. This helical polypeptide destabilizes the mitochondrial outer membrane, leading to the overproduction of intracellular reactive oxygen species (ROS) and apoptosis. In addition, this oxidative stress triggers ER stress-mediated ICD. The in vivo results show that cotreatment of fluorinated MDHP and antiprogrammed death-ligand 1 antibodies (alpha PD-L1) significantly regresses tumor growth and prevents metastasis to the lungs by activating the cytotoxic T cell response and alleviating the immunosuppressive tumor microenvironment. These results indicate that fluorinated MDHP synergizes with the immune checkpoint blockade therapy to eliminate established tumors and to elicit antitumor immune responses.en_US
dc.description.sponsorshipS.D.J. and B.-K.J. contributed equally to this work. This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (NRF-2019R1A4A1024116, NRF-2019R1A2C2085962, and NRF-2018M3A9E2024583 to Y.C.K. and NRF-2016M3A9B5942352 to C.-O.Y.) and the Korea Drug Development Fund (KDDF) funded by MSIT, MOTIE, and MOHW (KDDF-201904-23 to C.-O.Y.).en_US
dc.languageenen_US
dc.publisherWILEYen_US
dc.subjectcombination cancer immunotherapy; immune checkpoint blockade; im-munogenic cell death; mitochondrial membrane destabilization; ๐›ผ-helical polypeptideen_US
dc.titleImmunogenic Cell Death Inducing Fluorinated Mitochondria-Disrupting Helical Polypeptide Synergizes with PD-L1 Immune Checkpoint Blockadeen_US
dc.typeArticleen_US
dc.relation.no7-
dc.relation.volume8-
dc.identifier.doi10.1002/advs.202001308en_US
dc.relation.page308-308-
dc.relation.journalADVANCED SCIENCE-
dc.contributor.googleauthorJeong, Seong Dong-
dc.contributor.googleauthorJung, Bo-Kyeong-
dc.contributor.googleauthorAhn, Hyo Min-
dc.contributor.googleauthorLee, DaeYong-
dc.contributor.googleauthorHa, JongHoon-
dc.contributor.googleauthorNoh, Ilkoo-
dc.contributor.googleauthorYun, Chae-Ok-
dc.contributor.googleauthorKim, Yeu-Chun-
dc.relation.code2021000952-
dc.sector.campusS-
dc.sector.daehakCOLLEGE OF ENGINEERING[S]-
dc.sector.departmentDEPARTMENT OF BIOENGINEERING-
dc.identifier.pidchaeok-


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE